A surprisingly wide range of conditions produce blood abnormalities that look like leukemia on initial testing, from common infections and vitamin deficiencies to autoimmune diseases and the side effects of certain medications. In many documented cases, patients have been provisionally diagnosed with acute leukemia only for further testing to reveal a completely different, sometimes easily treatable, underlying cause. Understanding these mimics matters because misidentification can lead to unnecessary aggressive treatment or, in the other direction, delayed recognition of something that does need urgent care.
Infections That Look Like Blood Cancer
Certain infections are among the most convincing leukemia imposters, particularly those caused by Epstein-Barr virus (EBV). EBV, best known for causing infectious mononucleosis (“mono”), infects immune cells and can trigger such dramatic changes in blood counts that clinicians initially suspect acute leukemia. Because the virus directly targets the same white blood cells that become malignant in leukemia, infected cells can look strikingly abnormal under a microscope. Published case reports describe young adults diagnosed with acute leukemia based on atypical cells in peripheral blood who turned out to have classical infectious mononucleosis or EBV-related complications instead.1PubMed Central. Epstein-barr virus infection masquerading as acute leukemia: a report of two cases and review of literature One detailed case showed such high similarity to acute lymphoblastic leukemia that it significantly complicated the diagnostic process before EBV was confirmed.2Case Reports in Clinical Practice. Infectious Mononucleosis Mimicking Acute Lymphoblastic Leukemia (ALL): a Case Report
The confusion tends to arise because both leukemia and severe EBV infection can produce high white blood cell counts, enlarged lymph nodes, fatigue, fever, and an enlarged spleen. A standard blood smear may show large, unusual-looking lymphocytes that a less experienced lab technician could flag as blasts, the immature cells characteristic of leukemia. The key difference is that EBV-driven abnormalities are reactive and temporary. Specialized testing, including flow cytometry and viral serology, eventually separates the two, but the initial clinical picture can be genuinely alarming.
Tuberculosis is another infection that can masquerade as a blood disorder. When TB spreads beyond the lungs and infiltrates the bone marrow, it can cause pancytopenia, a drop in all three major blood cell lines (red cells, white cells, and platelets). This pattern is also a hallmark of leukemia. A bone marrow biopsy in such cases may reveal granulomas characteristic of TB rather than malignant cells, but only if the pathologist is looking for them.3PubMed Central. Extrapulmonary Tuberculosis in the Bone Marrow: A Case of Pancytopenia and Chronic Corticosteroid Use In regions where TB is common, this overlap is a well-recognized diagnostic pitfall.
Vitamin B12 Deficiency
One of the more treatable conditions that mimics leukemia is simple vitamin B12 deficiency. When B12 levels drop low enough, the bone marrow starts producing abnormal, immature-looking blood cells. The resulting picture can include pancytopenia, oddly shaped red blood cells, and even cells that resemble the blasts seen in acute leukemia or myelodysplastic syndromes. These changes can be so pronounced that they prompt a full leukemia workup, including bone marrow biopsy.4PubMed Central. Vitamin B12 deficiency mimicking acute leukemia
This mimicry is not limited to adults. A report described a 14-month-old child who presented with chronic fever, poor feeding, and severe paleness for a year. Blood work showed pancytopenia along with about 19% reactive or atypical cells in the peripheral blood, a finding that strongly suggested acute leukemia. The actual diagnosis turned out to be B12 deficiency.5PubMed Central. Vitamin B12 Deficiency Resembling Acute Leukemia: A Case Report Because B12 deficiency is a reversible cause of bone marrow suppression, checking vitamin levels before committing to a leukemia diagnosis is a simple step that can save patients from unnecessary invasive procedures or even chemotherapy.
The mechanism behind this confusion makes intuitive sense. B12 is essential for DNA synthesis. Without enough of it, cells that divide rapidly, like blood cell precursors in the bone marrow, fail to mature properly. The result is a buildup of large, immature-looking cells that genuinely resemble malignant blasts on morphology alone. Only additional testing, including B12 level measurement and more detailed bone marrow analysis, reveals the benign cause.
Leukemoid Reactions
A leukemoid reaction is exactly what it sounds like: a blood response that looks like leukemia but is not. It is defined by a persistent white blood cell count above 50,000 cells per microliter when the cause is something other than leukemia. The primary triggers are severe infections, certain toxins, other types of cancer, major hemorrhage, and acute destruction of red blood cells.6European Journal of Internal Medicine. An update on leukemoid reactions
These reactions can send white blood cell counts to levels normally associated with chronic myelogenous leukemia (CML). The diagnostic challenge centers on ruling out CML and chronic neutrophilic leukemia while identifying the actual underlying cause, which could be anything from a severe urinary tract infection to a hidden solid tumor. A few specific lab tests help differentiate the two. CML, for instance, is driven by a specific chromosomal abnormality (the Philadelphia chromosome), so testing for it quickly resolves the ambiguity. But until those results come back, the clinical picture can look indistinguishable from a chronic leukemia.
Solid Tumors That Spread to Bone Marrow
Cancers that originate in organs outside the blood system, like the prostate, breast, or lung, can sometimes spread to the bone marrow. When they do, they disrupt normal blood cell production and may release immature cells into the bloodstream in a pattern called leukoerythroblastosis. This peripheral blood picture, with its mix of immature white cells and nucleated red blood cells, is a classic indicator of marrow infiltration.7PubMed Central. Cytomorphological evaluation of non-haematopoietic malignancies metastasizing to the bone marrow In one study of over 100 cases with bone marrow metastasis from solid tumors, about a third showed immature granulocytes and nucleated red blood cells in peripheral blood.8PubMed Central. Bone Marrow Metastasis in Nonhematological Malignancies: A Study from Tertiary Care Center
These findings can easily be interpreted as a primary blood cancer, particularly when the original solid tumor has not been identified yet. A case report described a man with advanced prostate cancer who presented with shortness of breath, anemia, and low platelets. His peripheral blood showed leukoerythroblastosis, and only bone marrow examination revealed that prostate cancer cells had infiltrated the marrow extensively.9PubMed Central. Leukoerythroblastosis in castration-resistant prostate cancer: A clue to diffuse bone marrow carcinomatosis For patients where the primary cancer is unknown, this overlap can delay the correct diagnosis significantly.
Lymphomas, which are cancers of the lymphatic system rather than the bone marrow, can also enter a “leukemic phase” in which malignant lymphoma cells flood the bloodstream. When this happens, the blood picture looks very similar to certain types of leukemia. Distinguishing between lymphoma that has spilled into the blood and a true leukemia that originated there requires immunologic marker testing and often molecular analysis.10The American Journal of Medicine. Characterization of malignant lymphomas in leukemic phase by multiple differentiation markers of mononuclear cells The distinction matters because the treatment strategies for lymphoma and leukemia differ substantially even when both involve the same cell type.
Myelodysplastic Syndromes and the Gray Zone
Myelodysplastic syndromes (MDS) sit in an uncomfortable gray zone between normal bone marrow and outright leukemia. MDS involves abnormal blood cell production in the bone marrow, and some forms feature elevated numbers of immature blast cells. Traditionally, the line between MDS and acute myeloid leukemia (AML) has been drawn at 20% blasts in the marrow or blood, with anything above that threshold classified as AML.11Blood. Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal
In practice, this rigid cutoff creates odd situations. A patient with 19% blasts falls into the MDS category and is generally excluded from AML clinical trials, while a patient at 21% gets an AML diagnosis. Biologically and clinically, researchers have questioned whether this hard line makes sense, given that MDS and AML exist on a spectrum and share many of the same genetic mutations.12PubMed Central. Navigating the contested borders between myelodysplastic syndrome and acute myeloid leukemia Some MDS cases eventually transform into AML, which underscores how closely related these conditions are. For patients, the practical effect of this ambiguity is that a diagnosis can shift between MDS and AML depending on when the blood or marrow is sampled, and the distinction influences which treatments are offered.
Aplastic Anemia and Bone Marrow Failure
Aplastic anemia, a condition in which the bone marrow fails to produce enough blood cells, creates diagnostic confusion from the opposite direction. Instead of showing too many abnormal cells, the marrow is underpopulated. But when a form of AML called hypoplastic AML occurs, it produces a similarly empty-looking marrow. Distinguishing between aplastic anemia, hypocellular MDS, and hypoplastic AML poses a genuine challenge even for experienced hematologists because the blood counts and marrow appearance overlap substantially.13Journal of Advances in Medicine and Medical Research. Diagnostic Challenging Case of Hypoplastic Acute Myeloid Leukemia with Literature Review
The stakes of getting this wrong are high. Aplastic anemia is typically treated with immunosuppressive therapy or bone marrow transplant, while AML requires chemotherapy. Giving immunosuppression to someone who actually has leukemia would be disastrous, and vice versa. The overlap is another area where advanced molecular and genetic testing has become critical for accurate diagnosis.
Immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, can also raise suspicion for leukemia, especially in children. Both conditions cause easy bruising and low platelet counts. One study found that children with acute lymphoblastic leukemia actually had elevated immature platelet fractions, similar to what is seen in ITP, which complicates the initial differentiation.14PubMed. Immature platelet count: a simple parameter for distinguishing thrombocytopenia in pediatric acute lymphocytic leukemia from immune thrombocytopenia When a child presents with unexplained low platelets, clinicians often order a blood smear and sometimes a bone marrow biopsy specifically to exclude leukemia before starting ITP treatment.
Autoimmune and Inflammatory Conditions
Systemic autoimmune diseases can produce blood count abnormalities that overlap with leukemia. Systemic lupus erythematosus (SLE), for example, frequently causes cytopenias, meaning drops in one or more blood cell lines. When a patient with SLE develops leukocytosis (high white cell count), anemia, and thrombocytopenia simultaneously, the combination echoes the blood picture of leukemia.15PubMed Central. Challenges in diagnosing concurrent acute leukemia in an immunosuppressed patient with systemic lupus erythematosus: A case report Making matters more complicated, patients on immunosuppressive therapy for autoimmune diseases have a slightly elevated risk of actually developing blood cancers, so clinicians cannot simply dismiss abnormal counts as “just the lupus.”
Hemophagocytic lymphohistiocytosis (HLH) is another inflammatory condition that can be confused with leukemia. HLH involves an extreme, uncontrolled activation of the immune system. It causes high fevers, enlarged organs, and severe drops in blood counts, all features shared with aggressive leukemias. In at least one reported case, HLH was initially mistaken for progressive chronic lymphocytic leukemia because of the overlapping clinical and laboratory features.16PubMed Central. Hemophagocytic lymphohistiocytosis masquerading as progressive chronic lymphocytic leukemia HLH can also be triggered by EBV infection, circling back to the viral mimics discussed earlier and sometimes creating a layered diagnostic puzzle where infection, immune overactivation, and suspected malignancy all appear to coexist.
Medications That Alter Blood Counts
Several classes of medications can produce blood abnormalities that trigger concern about leukemia. Growth factors, drugs given to stimulate blood cell production (often after chemotherapy), have been documented to cause a temporary surge in blast cells in both the bone marrow and peripheral blood. A report of six such cases described marked but temporary increases in blasts that created genuine diagnostic confusion with acute leukemia relapse or progression of myelodysplastic syndromes.17American Journal of Clinical Pathology. Transient Increase in Blasts Mimicking Acute Leukemia and Progressing Myelodysplasia in Patients Receiving Growth Factor The increase was transient, resolving once the growth factor was stopped, but it was alarming enough to prompt additional biopsies and treatment discussions in the interim.
On the other end of the spectrum, certain drugs can cause agranulocytosis, a dangerous drop in neutrophils (a type of white blood cell) that mimics the bone marrow failure seen in some leukemias. Drug-induced agranulocytosis is rare but serious, and it can progress from no symptoms to life-threatening infection rapidly. The list of medications that can cause it is long and includes some commonly prescribed drugs like certain thyroid medications, antipsychotics, and antibiotics. When a patient’s neutrophil count plummets without an obvious explanation, leukemia is one of the first things clinicians want to rule out, even when the actual culprit is sitting in the patient’s medicine cabinet.
A Pediatric-Specific Mimic in Down Syndrome
Newborns with Down syndrome face a unique diagnostic situation. About 10% develop a condition called transient myeloproliferative disorder (TMD), sometimes referred to as transient leukemia. TMD is characterized by large numbers of immature megakaryoblasts (platelet precursor cells) flooding the peripheral blood, often with variable platelet counts.18PubMed. Transient myeloproliferative disorder (transient leukemia) and hematologic manifestations of Down syndrome Under a microscope, it is genuinely indistinguishable from a type of leukemia called acute megakaryoblastic leukemia.
The word “transient” is critical. In most affected newborns, TMD resolves on its own without treatment. A Children’s Oncology Group study confirmed that TMD, while sometimes lethal, is distinguished from true leukemia by its spontaneous resolution in the majority of cases.19PubMed Central. Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children’s Oncology Group Study A2971 However, a small percentage of children who have TMD at birth go on to develop true leukemia within the first few years of life, so the condition requires monitoring even after it appears to clear. The existence of TMD is a striking example of how biology can produce something that looks identical to cancer but behaves entirely differently.
Storage Diseases and Rare Overlaps
Some rare metabolic conditions create cellular appearances that overlap with leukemia at the microscopic level. Gaucher disease, for instance, involves the accumulation of a specific fatty substance in macrophages, producing distinctive “Gaucher cells” in the bone marrow. Interestingly, chronic myelogenous leukemia can produce cells that look nearly identical, called pseudo-Gaucher cells, because the rapid turnover of white blood cells in CML overwhelms the macrophages’ ability to process cellular waste. These pseudo-Gaucher cells are sometimes found during the initial workup for CML, and in rare cases, distinguishing between actual Gaucher disease and a leukemia producing look-alike cells requires enzymatic testing.20PubMed Central. Gaucher disease and chronic myeloid leukemia: first reported patient receiving enzyme replacement and tyrosine kinase inhibitor therapies simultaneously This overlap is admittedly unusual, but it illustrates how even cellular morphology, the traditional backbone of blood cancer diagnosis, has its limits.
Why Morphology Alone Is Not Enough
Many of these diagnostic confusions stem from an over-reliance on how cells look under a microscope. Morphological analysis, where a trained specialist examines a stained blood or marrow smear, was the gold standard for leukemia diagnosis for decades. It remains an important first step, but its limitations are well documented. A study evaluating acute leukemia diagnosis found that morphology combined with chemical staining correctly classified the vast majority of AML cases but missed a meaningful number of acute lymphoblastic leukemia cases, particularly certain AML subtypes that closely resemble ALL under the microscope.21PubMed Central. Evaluation of Acute Leukaemias by Flow Cytometry and Its Correlation With Diagnosis Using Morphological and Special Staining Techniques
Flow cytometry, which identifies cells based on proteins on their surface rather than visual appearance, has become essential for resolving ambiguous cases. It can differentiate reactive (infection-driven) cell populations from malignant ones, distinguish between subtypes of leukemia, and identify cells from solid tumors that have invaded the marrow. Molecular testing, including analysis of specific gene mutations and chromosomal changes, adds another layer of precision. The combination of these tools is why patients today are far less likely to be misdiagnosed with leukemia than they were even 20 years ago, though the initial blood work can still cause genuine alarm before more definitive results are available.
When to Worry and When to Wait
If you have received preliminary blood results that raise concern about leukemia, the most important thing to understand is that preliminary results are exactly that. An abnormal complete blood count, unusual cells on a smear, or even a concerning bone marrow finding is the beginning of a diagnostic process, not the end. Many of the conditions described here, from B12 deficiency to viral infections to medication effects, are identified through follow-up testing that is routinely performed before a leukemia diagnosis is finalized.
There are, however, some patterns that more strongly suggest a benign mimic rather than true leukemia. Recent onset of symptoms coinciding with a viral illness, a known history of autoimmune disease, current medication that affects blood counts, or a dietary history consistent with nutritional deficiency all provide context that shifts the probability. Conversely, unexplained weight loss, drenching night sweats, persistent bone pain, and progressively worsening blood counts over weeks tend to raise suspicion for an actual malignancy. Neither set of features is definitive on its own, which is why hematologists rely on layered testing rather than any single finding.
For parents of children with Down syndrome, awareness of TMD can be particularly valuable. Knowing that about one in ten newborns with trisomy 21 will develop a transient leukemia-like blood picture, and that it usually resolves on its own, provides important context if a pediatric hematologist is suddenly involved in your newborn’s care. Monitoring rather than immediate aggressive treatment is typically the right approach, though ongoing follow-up is needed given the small but real risk of later true leukemia developing.